Nimotuzumab + S-1

The combination of nimotuzumab and S-1 is a therapeutic regimen that has been studied in various cancer types, particularly in advanced gastric cancer and esophageal squamous cell carcinoma. Nimotuzumab is a humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), while S-1 is an oral fluoropyrimidine anticancer agent. ## Efficacy and Clinical Trials Several clinical trials have evaluated this combination, often with cisplatin added as a third component. A randomized phase II trial compared nimotuzumab plus S-1 and cisplatin (NCS) versus S-1 and cisplatin (CS) alone in patients with untreated unresectable or metastatic gastric cancer[1][6]. Interestingly, the results showed that adding nimotuzumab did not provide additional benefit compared to chemotherapy alone in this setting. The objective response rate was 54.8% for NCS versus 58.1% for CS alone[1][10]. In terms of survival outcomes, median progression-free survival was actually better in the CS arm (7.2 months) compared to the NCS arm (4.8 months)[1][10]. There was also a trend toward better overall survival for patients in the CS arm (14.3 months vs. 10.2 months)[10]. More promising results have been seen in other cancer types. For locally advanced esophageal squamous cell carcinoma (LA-ESCC), S-1 plus nimotuzumab-based concurrent chemoradiotherapy has shown reasonable efficacy and promising safety in patients who failed neoadjuvant chemotherapy or chemoimmunotherapy[8]. ## Safety Profile The combination therapy appears to be generally well-tolerated. In clinical trials, the incidence of adverse events was similar between treatment groups with and without nimotuzumab[6]. Reported adverse events included grade 3/4 hypo-hemoglobin (13.33%/7.41%), grade 3/4 thrombocytopenia (3.33%/0), and grade 3/4 neutropenia (3.33%/0)[6]. One patient experienced grade 3/4 digestive side effects (3.33%/0)[6]. Nimotuzumab has demonstrated a better safety profile than other anti-EGFR antibodies due to its intermediate affinity[4]. It rarely causes severe dermatological toxicity, which is the most common adverse event resulting from other EGFR inhibitors like cetuximab and panitumumab[7]. ## Mechanism of Action Nimotuzumab works by blocking the binding of EGF and TGF-alpha to EGFR, inhibiting tumor cell growth, angiogenesis, and promoting apoptosis[4][7]. When combined with S-1, which is an oral fluoropyrimidine that inhibits DNA synthesis, the regimen targets cancer through multiple mechanisms. This combination continues to be studied in various cancer types, with ongoing research to determine the optimal patient populations that might benefit most from this approach.

Brand names

CIMAherBIOMAb EGFRTS-1TS1TS 1Teysuno

Other names

nimotuzumab plus S-1nimotuzumab + S1